A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 4, 2010, Pages 344-348

  Hennekens, Charles H ^a,b   Schneider, Wendy R ^a,b   Pokov, Alex ^c   Hetzel, Scott ^d   Demets, David ^d   Serebruany, Victor ^c   Schröder, Henning ^e  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c HeartDrug Research Laboratories   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

atherosclerosis; cardiovascular disease; endothelium; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; HEME OXYGENASE 1; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN SYNTHASE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; COMPETITIVE INHIBITION; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 78651331360     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410375091     Document Type: Article

References (12)

1. Vane JR Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 ; 231 (25). 232-235.
2. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ. 2002 ; 324 (7329). 71-86.
3. Antithrombotic Trialists Collaboration Primary Prevention Writing Group. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data. Lancet. 2009 ; 373 (9678). 1849-1860.
4. Schröder H. Nitric oxide and aspirin: a new mediator for an old drug. Am J Ther. 2009 ; 16 (1). 17-23.
5. Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006 ; 113 (13). 1708-1714.
6. Grosser N., Schröder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol. 2003 ; 23 (8). 1345-1351.
7. Paul-Clark MJ, van Cao T., Moradi-Bidhendi N., Cooper D., Gilroy DW. 15-Epi-lipoxin A(4)-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med. 2004 ; 200 (1). 69-78.
8. Nascimento-Silva V., Arruda MA, Barja-Fidalgo C., Villela CG, Fierro IM Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol. 2005 ; 289 (3). C557 - C563.
9. O'Kane P., Xie L., Liu Z., et al. Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res. 2009 ; 83 (1). 123-130.
10. Grosser N., Abate A., Oberle S., et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003 ; 308 (4). 956-960.
11. Malinski T., Radomski MW, Taha Z., Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun. 1993 ; 194 (2). 960-965.
12. Cardounel AJ, Cui H., Samouilov A., et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. 2007 ; 282 (2). 879-887.